Adolor to Host Investor Conference Call to Discuss the FDA Approval of Entereg(R) (alvimopan)

  
    
  
  
    
      Adolor Corporation (NASDAQ:ADLR) will be hosting an investor conference 
      call and webcast on Wednesday, May 21, 2008 at 8:30 a.m. Eastern Time to 
      discuss the U.S. Food and Drug Administration (FDA) approval of Entereg® 
      (alvimopan) capsules to help patients regain gastrointestinal function 
      earlier following bowel resection surgery.
    
    
      To participate in the audio portion and have the opportunity to pose 
      questions, dial 1-877-726-1721 for domestic callers and 1-706-902-2930 
      for international callers and enter Conference ID #48212826. An audio 
      webcast also will be available on the Investor Relations section of 
      Adolor's website, www.adolor.com.
    
    
      A replay of the conference call will be available beginning at 10:00 
      a.m. Eastern Time on May 21, 2008. To listen to a replay of the 
      conference call, dial 1-800-642-1687 (domestic callers) or 
      1-706-645-9291 (international callers) and enter Conference ID #48212826 
      or listen via Adolor's website. The replay will be available for one 
      week.
    
    
      About Adolor Corporation
    
    
      Adolor Corporation (Nasdaq:ADLR) is a biopharmaceutical company 
      specializing in the discovery, development and commercialization of 
      novel prescription pain management products. By applying its knowledge 
      and expertise in pain management, along with ingenuity, Adolor is 
      seeking to make a positive difference for patients, caregivers and the 
      medical community. For more information, visit www.adolor.com.
    
    
      Adolor Forward-Looking Statements
    
    
      This release, and oral statements made with respect to information 
      contained in this release, may constitute forward-looking statements 
      within the meaning of the Private Securities Litigation Reform Act of 
      1995. Such forward-looking statements include those which express 
      plan, anticipation, intent, contingency, goals, targets or future 
      development and/or otherwise are not statements of historical fact. These 
      statements are based upon management's current expectations and are 
      subject to risks and uncertainties, known and unknown, which could cause 
      actual results and developments to differ materially from those 
      expressed or implied in such statements. Such known risks and 
      uncertainties relate to, among other factors: the risk that Entereg may 
      not be a commercial success; the uncertainty of market acceptance of 
      Entereg, including acceptance by hospitals, physicians, payors or the 
      medical community; the risk that the Risk Evaluation and 
      Mitigation Strategy or REMS, including the registration of hospitals 
      could materially adversely affect the commercial prospects for ENTEREG 
      or negatively impact the uptake of Entereg, the risks associated with 
      government regulations relating to marketing and selling pharmaceutical 
      products; the risk of product liability claims; the risks of reliance on 
      third party manufacturers; the risk of competitive products; the risk 
      that the alvimopan Investigational New Drug Application (IND) for OBD 
      remains on clinical hold indefinitely; the risk that Entereg may not be 
      approved in OBD or any indication other than the FDA approved indication 
      in bowel resection surgery; the risk that filing targets for regulatory 
      submissions are not met; the risk that the results of other clinical 
      trials of Adolor's drug products and drug product candidates, including 
      ENTEREG, are not positive or do not support safety or efficacy; the 
      costs, delays and uncertainties inherent in scientific research, drug 
      development, clinical trials and the regulatory approval process; the 
      changing regulatory environment; risks associated with intellectual 
      property protection for Adolor’s products and 
      third party intellectual property; Adolor's history of operating losses 
      since inception and its need for additional funds to operate its 
      business; Adolor's reliance on its collaborators, including GSK, in 
      connection with the development and commercialization of ENTEREG; market 
      acceptance of Adolor's products, if regulatory approval is achieved; 
      competition; and securities litigation.
    
    
      Further information about these and other relevant risks and 
      uncertainties may be found in Adolor's Reports on Form 8-K, 10-Q and 
      10-K filed with the U.S. Securities and Exchange Commission. Adolor 
      urges you to carefully review and consider the disclosures found in its 
      filings which are available in the SEC EDGAR database at http://www.sec.gov 
      and from Adolor at http://www.adolor.com. 
      Given the uncertainties affecting pharmaceutical companies in the 
      development stage, you are cautioned not to place undue reliance on any 
      such forward-looking statements, any of which may turn out to be wrong 
      due to inaccurate assumptions, unknown risks, uncertainties or other 
      factors. Adolor undertakes no obligation to (and expressly 
      disclaims any such obligation to) publicly update or revise the 
      statements made herein or the risk factors that may relate thereto 
      whether as a result of new information, future events, or otherwise.